Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alvotech ALVO

Healthcare  —  Drug Manufacturers Specialty & Generic
5.75 (0.13) (2.21%) as of 25 Sep
Market cap
$2.3B
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Alvotech (ALVO) Business Profile

Updated before January 2025

Company Overview

Alvotech (NASDAQ: ALVO) is a global biopharmaceutical company specializing in the development and manufacturing of biosimilar medicines. Founded in 2013 by Robert Wessman, Alvotech is headquartered in Reykjavik, Iceland. The company was established with the vision of improving patient access to affordable, high-quality biologics. Alvotech operates with a strong leadership team, including Robert Wessman as Chairman and Mark Levick as CEO, both of whom bring extensive experience in the pharmaceutical and biotechnology industries. The company has rapidly grown into a key player in the biosimilars market, leveraging its state-of-the-art facilities and a highly skilled workforce.

Core Business Segments

Alvotech focuses on the development, manufacturing, and commercialization of biosimilar medicines. Its core business segments include:

Biosimilar Development

Alvotech specializes in creating biosimilar versions of blockbuster biologic drugs. These biosimilars are designed to offer the same therapeutic benefits as their reference products but at a significantly lower cost. Key products in this segment include biosimilars for autoimmune diseases, oncology, and other chronic conditions. Notable biosimilars in Alvotech’s pipeline include:

  • AVT02: A biosimilar to Humira® (adalimumab), used to treat autoimmune diseases such as rheumatoid arthritis and Crohn’s disease.
  • AVT04: A biosimilar to Stelara® (ustekinumab), targeting conditions like psoriasis and Crohn’s disease.
  • AVT06: A biosimilar to Eylea® (aflibercept), used in the treatment of retinal diseases.

Manufacturing Services

Alvotech operates a vertically integrated manufacturing facility in Reykjavik, Iceland. This facility is equipped with cutting-edge technology to ensure the production of high-quality biosimilars. The company also offers contract manufacturing services to other biopharmaceutical companies, leveraging its expertise in biologics production.

Commercial Partnerships

Alvotech collaborates with global pharmaceutical companies to commercialize its biosimilars in various markets. These partnerships enable the company to expand its reach and ensure that its products are accessible to patients worldwide.

Business Model

Alvotech’s business model is built on vertical integration, which allows the company to control every aspect of the biosimilar development process, from research and development to manufacturing and commercialization. This approach ensures high-quality standards, cost efficiency, and faster time-to-market for its products. The company generates revenue through:

  • Product Sales: Direct sales of biosimilars to healthcare providers and distributors.
  • Licensing Agreements: Partnering with pharmaceutical companies for the commercialization of its products in specific regions.
  • Contract Manufacturing: Offering manufacturing services to other biopharmaceutical companies.

Strategic Direction

Alvotech is committed to expanding its biosimilar portfolio and entering new therapeutic areas. The company’s strategic priorities include:

  • Pipeline Expansion: Developing biosimilars for additional blockbuster biologics to address unmet medical needs.
  • Global Market Penetration: Strengthening its presence in key markets, including the United States, Europe, and Asia.
  • Sustainability Goals: Implementing environmentally friendly practices in its manufacturing processes to reduce its carbon footprint.
  • Innovation: Investing in advanced technologies to enhance the efficiency and quality of its biosimilar development and production.

Competitive Landscape

Alvotech operates in a highly competitive biosimilars market, facing competition from both established pharmaceutical companies and specialized biosimilar developers. Key competitors include:

  • Sandoz: A division of Novartis, known for its extensive biosimilar portfolio.
  • Amgen: A leading biotechnology company with a strong presence in the biosimilars market.
  • Samsung Bioepis: A joint venture between Samsung Biologics and Biogen, focused on biosimilar development.
  • Celltrion: A South Korean biopharmaceutical company specializing in biosimilars.

Despite the competition, Alvotech differentiates itself through its vertical integration, cost-efficient manufacturing, and strategic partnerships.

Risk Factors

Alvotech faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Challenges: The biosimilar approval process is complex and varies across regions, posing potential delays and additional costs.
  • Market Dependence: Reliance on a limited number of products for revenue generation increases vulnerability to market fluctuations.
  • Supply Chain Disruptions: Dependence on raw materials and third-party suppliers could lead to production delays.
  • Competition: Intense competition in the biosimilars market may pressure pricing and market share.

Recent Developments

Alvotech has made significant progress in recent years, including:

  • Regulatory Approvals: Securing approval for AVT02 in multiple markets, including the European Union and Canada.
  • Partnerships: Expanding its global reach through partnerships with companies like Teva Pharmaceuticals and STADA Arzneimittel.
  • Facility Expansion: Investing in its manufacturing facility to increase production capacity and meet growing demand.
  • Innovation: Advancing its pipeline with the development of next-generation biosimilars.

Investment Considerations

Strengths

  • Strong Pipeline: A robust portfolio of biosimilars targeting high-demand therapeutic areas.
  • Vertical Integration: Control over the entire development and manufacturing process ensures quality and cost efficiency.
  • Global Partnerships: Collaborations with leading pharmaceutical companies enhance market access.

Risks

  • Regulatory Hurdles: Potential delays in product approvals could impact revenue.
  • Market Competition: Intense competition may affect pricing and profitability.
  • Supply Chain Risks: Dependence on third-party suppliers poses potential challenges.

Conclusion

Alvotech is well-positioned in the biosimilars market, with a strong pipeline, advanced manufacturing capabilities, and strategic partnerships. The company’s focus on innovation and sustainability, combined with its commitment to improving patient access to affordable biologics, underscores its growth potential. While challenges such as regulatory hurdles and market competition remain, Alvotech’s strategic direction and operational strengths make it a promising player in the biopharmaceutical industry.